Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors
Retrieved on:
Wednesday, November 15, 2023
The company is also announcing the appointment of Tony Fadell to its Board of Directors.
Key Points:
- The company is also announcing the appointment of Tony Fadell to its Board of Directors.
- ORB-011 is a first-in-class modified interferon designed to act with a high level of precision on cDC1 dendritic immune cells, potent activators of tumor cell killing CD8+ T cells.
- Preclinical research has shown that selective activation of cDC1s with such conditionally active interferon molecules translates into effective antitumor activity.
- ORB-011 has the potential to harness the therapeutic activity of interferon in a new way,” said Nikolai Kley, Ph.D., Founder, President, and Chief Executive Officer of Orionis Biosciences.